TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03072602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study diet
Description: Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study diet
Description: Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Challenge
Description: Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Challenge
Description: Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
Study: NCT04108429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare for College Students
Description: Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
Study: NCT00546975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resource Support®

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resource Protein®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01213030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18] FMISO
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18] HX4
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Study: NCT02342834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small mixed protein and lipid meal
Description: Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
Study: NCT00152867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 4mg PO bd for 2 days post chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 4mg PO bd for 2 days post chemotherapy
Study: NCT02527707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyltransferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Cytochromes P450 3A4 inhibitor used to boost lonafarnib
Study: NCT01569984

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Avastin 7.5 mg/kg IV x 2 doses 14 days apart
Study: NCT02113787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic study
Description: Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic study
Description: Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
Study: NCT03345056

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vitrectomy with planned foveal detachment
Description: 23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
Study: NCT03936387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
Study: NCT05662267

Intervention type: OTHER
Intervention: Pancreatic islet transplantation after kidney transplantation
Description: Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
Study: NCT01812902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Study: NCT03185689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of an intensified DSME in T2D adult patients
Study: NCT04153084

Intervention type: DRUG
Intervention: Polyethylene Glycol 4000 with electrolytes
Description: The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.

Intervention type: DRUG
Intervention: PEG-3350 with electrolytes
Description: The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.

Intervention type: DRUG
Intervention: Sodium picosulfate
Description: The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night.
Study: NCT01769937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
Study: NCT00800215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv SPM 927 and oral placebo tablet
Description: 60-minute infusion iv SPM 927 and oral placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral SPM 927 tablet and iv placebo
Description: 60-minute infusion placebo and oral SPM 927 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv SPM 927 and oral placebo tablet
Description: 30-minute infusion iv SPM 927 and oral placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral SPM 927 tablet and iv placebo
Description: 30-minute infusion placebo and oral SPM 927 tablet
Study: NCT01653730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse 3 portable oxygen concentrator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverGo portable oxygen concentrator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iGo portable oxygen concentrator
Study: NCT00670007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1- proteinase inhibitor [human]
Description: Lyophilized preparation of 60 mg/kg body weight intravenously once per week
Study: NCT01241500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
Study: NCT01825902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo 18F-FLT PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo 18F-FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 18F-FLT PET and 18F-FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00325078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study: NCT01175746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: 0.1-0.5 ugkg/min during hypotensive anesthesia
Study: NCT01208129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB001
Description: nail lacquer, once daily, 52 weeks
Study: NCT02738723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP
Description: Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
Study: NCT02828917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedJ-01 Ridaforolimus Eluting Coronary Stent System
Study: NCT00006226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01208129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: nail lacquer, once daily, 52 weeks
Study: NCT03246828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omission of gliclazide
Description: Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
Study: NCT00984204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy Cool Path Duo
Description: All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
Study: NCT00581971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400mg bid starting 1 week before radiotherapy and taken through radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, AUC 2.0, weekly for weeks 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV 30 mg/m2, weekly for weeks 1 through 7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70.2Gy, at 1.8Gy qd, Monday through Friday
Study: NCT03828734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta TMS
Description: TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta TMS
Description: TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha TMS
Description: TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha TMS
Description: TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
Study: NCT02341261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise and Counseling
Study: NCT04464330

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study: NCT04300673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio guided surgery (RGS) using Indium-labelled PSMA
Description: Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
Study: NCT02392000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WatchPAT sleep monitor
Description: Self-management of insomnia using a mobile sleep device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-i Coach mobile app
Description: Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
Study: NCT03595696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Muscle Strength Training
Description: Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
Study: NCT04135027

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT04132778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
Study: NCT00842595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 6 courses every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 6 courses every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 6 courses every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 6 courses every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 6 courses every 28 days
Study: NCT00538083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
Study: NCT02970240

Intervention type: PROCEDURE
Intervention: Cardiopulmonary testing
Description: A 2-day consecutive testing on an ergometer cycle
Study: NCT02865356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 5% solution
Description: topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical vehicle solution
Study: NCT02970240

Intervention type: PROCEDURE
Intervention: Cardiopulmonary testing
Description: A 2-day consecutive testing on an ergometer cycle

Intervention type: PROCEDURE
Intervention: Cardiopulmonary testing
Description: A 2-day consecutive testing on an ergometer cycle
Study: NCT00726843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of Iyengar Yoga
Description: Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of Iyengar Yoga
Description: Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
Study: NCT04276558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udonitrectag
Description: Eye drop solution in single dose unit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udonitrectag
Description: Eye drop solution in single dose unit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udonitrectag
Description: Eye drop solution in single dose unit.
Study: NCT01985347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure( CPAP)
Study: NCT04276558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.
Study: NCT03595696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Muscle Strength Training
Description: Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
Study: NCT02151344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
Study: NCT04441970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral position
Description: The cuff pressure will be recorded at the neutral head position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head extension position
Description: The cuff pressure will be recorded at the head extension position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head flexion position
Description: The cuff pressure will be recorded at the head flexion position.
Study: NCT02151344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
Study: NCT02984800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB injection at L1-L2
Description: Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB injections at T12-L1, L1-L2 and L2-L3.
Description: Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
Study: NCT04788082

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Printed Heart Model
Description: Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
Study: NCT03320655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Aerobic Training
Description: The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Strength Training
Description: During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.